Trial
NCT02429934
Abatacept for SLE Arthritis (IM101-330)
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
University of California, Los Angeles
Collaborators
Bristol-Myers Squibb
Condition
Systemic Lupus Erythematosus Arthritis
Intervention
abatacept also known as Orencia also known as CTLA4-Ig
Why stopped
Response rate in placebo group for primary outcome was 100% on interim analysis.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-05-13